title: Effect of cholecalciferol on parathyroid hormone and vitamin D levels in chronic kidney disease.
abstract: OBJECTIVE
  We aimed to determine the effect of a monthly oral vitamin D on the serum 25-hydroxyvitamin D levels and iPTH levels in patients with CKD.
  
  
  METHODS
  This was a prospective controlled trial of 48 patients with CKD stage 3-4. Patients were divided into two groups Group1 the cholecalciferol treatment group, Group 2, the control group. One patient in Group 1, and 3 patients in Group2 were excluded after the baseline 25(OH)D levels were determined to be greater than 30ng/ml. Two patients in Group1, and one patient in Group 2 were excluded after the baseline iPTH was determined to be less than 70 pg/ml and greater than 300 pg/ml. Five patients in both groups were lost to follow-up. Thus, a total of 16 patients in Group 1 and 15 patients in Group2 completed the three month study. Group1 patients received 300,000 IU month oral cholecalciferol.
  
  
  RESULTS
  The mean serum 25(OH)D concentration of the group1 was significantly higher at baseline (P=0.039). At the end of the three months; serum 25 (OH) D level increased significantly in Group1 (P=0.001). iPTH level of Group1 was significantly lower at baseline (P=0.034). The values of the group1 before and end of third month was compared, serum Ca (P=0.011), P (P=0.013) level showed significant increase, but no significant increase in the Group 2 (P>0.05). The groups had not a clinically significant change in serum Ca and P level (P>0.05).
  
  
  CONCLUSIONS
  Oral cholecalciferol supplementation can be used safely and effective in reducing iPTH levels and correcting vitamin D insufficiency/deficiency in patients with CKD.
authors: Department of Nephrology, Bagcilar Research and Education Hospital, Istanbul, Turkey. tanerbast@yahoo.com
authors: T
authors: T
authors: Basturk
authors: A
authors: A
authors: Unsal
authors: T
authors: T
authors: Ulas
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002762:Cholecalciferol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000150:complications; D006801:Humans; D006961:Hyperparathyroidism / Q000209:etiology / Q000517:prevention & control*; D006973:Hypertension / Q000150:complications; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood*; D011446:Prospective Studies; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors; D016896:Treatment Outcome; D014807:Vitamin D / Q000097:blood
chemical_list: D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D014807:Vitamin D; D002762:Cholecalciferol